Named Bioactive Compounds · Compound
Chalcone
Moderate Evidencechalcone2 PubMed Studies
Hermetica Superfood Encyclopedia
Chalcone is a flavonoid precursor compound with an α,β-unsaturated ketone structure that exhibits potential antioxidant and anti-inflammatory properties. This bioactive molecule works through modulation of inflammatory pathways and free radical scavenging mechanisms.
Chalcone is an α,β-unsaturated ketone with the chemical formula C₆H₅C(O)CH=CHC₆H₅, representing the basic 1,3-diphenyl-2-propen-1-one structure. It is a naturally occurring secondary metabolite found in fruits, herbs, spices, teas, and legumes, synthesized in plants through the enzyme chalcone synthase. The characteristic keto-ethylenic group serves as a precursor to all other flavonoid groups.
The provided research dossier does not contain specific human clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs evaluating chalcone efficacy in clinical populations. The available sources focus on chemical synthesis, structural diversity, and general pharmacological properties rather than clinical outcomes data.
No clinically studied dosage ranges, standardization protocols, or dose-response data for chalcone are available in the current research. Consult a healthcare provider before starting any new supplement.
Chalcone (1,3-diphenyl-2-propen-1-one) is not a nutrient but a polyphenolic compound belonging to the flavonoid biosynthetic pathway. It is the open-chain precursor to flavanones via chalcone isomerase. Key profile: • Chemical formula: C₁₅H₁₂O (parent scaffold, MW ~208.26 g/mol); naturally occurring derivatives are hydroxylated/methoxylated (e.g., isoliquiritigenin, butein, xanthohumol). • Not consumed as an isolated macronutrient; found in trace quantities in dietary sources — licorice root (Glycyrrhiza glabra: isoliquiritigenin ~0.01–0.5% dry weight), hops (Humulus lupulus: xanthohumol ~0.1–1% dry weight of female inflorescences, translating to ~0.1–0.9 mg/L in beer), Angelica keiskei (4-hydroxyderricin ~0.01–0.1% fresh leaf weight), and certain citrus peels. • Bioactive compounds of note: isoliquiritigenin (MW 256.25), xanthohumol (MW 354.40), butein (MW 272.25), cardamonin (MW 270.28). • Contains no significant macronutrients (protein, fat, carbohydrate, fiber) when considered as a pure compound. • No vitamins or minerals inherent to the chalcone scaffold. • Bioavailability is generally low: oral bioavailability of xanthohumol estimated at ~0.1–0.3% in rodent models due to extensive first-pass metabolism, glucuronidation, and isomerization to isoxanthohumol in the gut. Isoliquiritigenin shows slightly higher absorption (~1–5% bioavailability in animal studies) but is rapidly conjugated by UDP-glucuronosyltransferases and sulfotransferases. • Chalcones are chemically reactive α,β-unsaturated ketones (Michael acceptors), which contributes to both their biological activity (Nrf2/Keap1 pathway activation, NF-κB inhibition) and rapid metabolic clearance. • Gut microbiota can convert certain chalcones (e.g., isoxanthohumol → 8-prenylnaringenin), affecting net bioactive exposure. • Dietary intake from normal food sources is estimated in the low microgram-to-low milligram range per day, well below doses used in preclinical studies (typically 10–100 mg/kg in animal models).
Chalcone compounds function through multiple molecular pathways, primarily by inhibiting nuclear factor-κB (NF-κB) signaling and reducing pro-inflammatory cytokine production. The α,β-unsaturated ketone structure enables Michael addition reactions with cellular nucleophiles, contributing to antioxidant activity. Specific chalcone derivatives like butein and isoliquiritigenin modulate cyclooxygenase and lipoxygenase enzymes involved in inflammatory cascades.
Clinical evidence for chalcone compounds remains limited, with most research conducted in preclinical cell culture and animal studies rather than human trials. Laboratory studies have demonstrated antioxidant capacity and anti-inflammatory effects at concentrations ranging from 10-100 μM in vitro. A few small pilot studies on chalcone-rich plant extracts showed modest anti-inflammatory markers in humans, but isolated chalcone supplementation lacks robust clinical validation. Current evidence quality is considered preliminary and requires larger, controlled human studies for definitive health benefit claims.
Chalcone compounds appear generally well-tolerated in small studies, though comprehensive safety data is lacking. Potential interactions may occur with anticoagulant medications due to possible effects on platelet aggregation observed in laboratory studies. Individuals with hormone-sensitive conditions should exercise caution as some chalcone derivatives demonstrate weak estrogenic activity. Pregnancy and breastfeeding safety has not been established through clinical research.
